A recent study by JABSOM researchers was published in JAMA Network Open.
IMPORTANCE Having diverse participants in clinical trials ensures new drug products work well
across different demographic groups, making health care safer and more effective for everyone.
Information on the extent of Native Hawaiian and Pacific Islander participation in clinical trials
is limited.
OBJECTIVE To examine representation of Native Hawaiian and Pacific Islanders in clinical trials
leading to the first US Food and Drug Administration (FDA) approvals for the 10 drug products with
the top worldwide sales forecasts in 2024.